Recent advances in the pharmacotherapy of schizophrenia.
The major advance in the psychopharmacology of schizophrenia has been the rediscovery of clozapine and the development of other novel antipsychotic drugs, all of which are superior to typical neuroleptic drugs with regard to extrapyramidal symptoms. Clozapine, the best studied of these agents, is also superior in efficacy with regard to psychopathology and cognitive function and has been shown not to cause tardive dyskinesia. A variety of other novel agents, e.g., risperidone, olanazpine, amperozide, seroquel, sertindole, zaprisidone and melperone, must be further studied to establish their efficacy relative to clozapine or the typical neuroleptics, or both. It is likely that these novel agents will displace the typical neuroleptic drugs as the primary treatment of schizophrenia.
Meltzer
H Y
HY
Laboratory of Biological Psychiatry, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106.
Lee
M A
MA
Ranjan
R
R
D000328:Adult; D014150:Antipsychotic Agents; D001921:Brain / Q000503:physiopathology; D003024:Clozapine / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D007555:Isoxazoles / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D010880:Piperidines / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D018967:Risperidone; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology
D014150:Antipsychotic Agents; D007555:Isoxazoles; D010880:Piperidines; D003024:Clozapine; D018967:Risperidone; D004298:Dopamine